Significant Differences in Effects of Sitagliptin Treatment on Body Weight and Lipid Metabolism Between Obese and Non-Obese Patients With Type 2 Diabetes

Abstract

Background: We previously reported that HbA1c levels and body weight significantly decreased by 0.6% and by 0.8 kg, respectively, at 6 months after sitagliptin treatment started. We found a significant and negative correlation between change in body weight and body mass index (BMI) at baseline.

A CROSS SECTIONAL STUDY IN NORTH EASTERN UTTAR PRADESH POPULATION FOR THE ESTIMATION OF BMI, HDL & TRIGLYCERIDES LEVELS IN RECENTLY DIAGNOSED PATIENTS WITH TYPE 2 DIABETES MELLITUS TAKING METFORMIN ALONE, METFORMIN WITH ADD ON SITAGLIPTIN AND SITAGLIPTIN ALONE.

“…(TABLE 3). Table 3 Result of our study is comparable to the studies conducted by Katsuyama et al [2] who had observed that Body weight and BMI in obese group were significantly greater than in non- Yanai et al [3] had found a significant and negative correlation between change in body weight and body mass index at baseline. After 6 months they found a significant reduction in body weight.…”

“…Other comparative studies reveal comparison of Lipid profiles include a study performed by Chawla S. et al [12] revealed a significant (p<0.01) decrease in High density lipoprotein (HDL-C) & a significant (p<0.01) decrease in Triglyceride, whereas Katsuyama et al [2] had also established that significant differences was seen in effects of Sitagliptin treatment on Another study performed by Sakamoto Y. et al [13] had demonstrated that serum levels of triglycerides and total cholesterol decreased significantly. (p<0.001).…”

A Croos Sectional Study in North Eastern Uttar Pradesh Population for the Estimation of Hdl, Triglycerides Levels in Recently Diagnosed Patients With Diabetes Mellitus Type 2 Taking Metformin Alone, Metformin With Add on Sitagliptin and Sitagliptin Alone

“…Result of our study is comparable to the studies conducted by Katsuyama et al [2] who had observed that Body weight and BMI in obese group were significantly greater than in nonobese group at baseline. After 6 months of initiating sitagliptin use, significant reduction in body weight in obese group, whereas no change was noted in non-obese group, whereas…”

“…Other comparative studies reveal comparison of Lipid profiles include a study performed by Chawla S. et al [12] revealed a significant (p<0.01) decrease in High density lipoprotein (HDL-C) & a significant (P<0.01) decrease in Triglyceride, whereas Katsuyama et al [2] had also established that significant differences was seen in effects of sitagliptin treatment on body weight and lipid metabolism between obese and non-obese patients with type 2 diabetes.…”

The changes of cholecystokinin and cannabinoid 1 peptide receptor in stomach and duodenum of Type 2 diabetic rats treated with dipeptidyl peptidase-4 inhibitor-sitagliptin.

“…Katsuyama ve ark. [14] Tip 2 diyabetik obez ve obez olmayan bireyler üzerinde yaptiklari çalişmalarinda, sitagliptinin vücut ağirliğini azaltiğini bildirmişlerdir.…”